
The abstracts below have been edited.
The full abstract of the Medical Journal articles are available on Pubmed.
To obtain them, search Pubmed for &&url
You can also search Pubmed for &&url


1. J Clin Oncol 2001 May 15;19(10):2596-606 
<b>Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.</b> 
Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, et.al. 
Rigshospitalet, Copenhagen, Denmark.  

"Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate. Our results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer." 
&&url PMID: 11352951 


2. J Exp Clin Cancer Res 2000 Mar;19(1):17-9 
<b>Letrozole for the treatment of pretreated advanced breast cancer patients: preliminary report.</b>
 Casali A, Sega FM, Casali M, Giuntini T, Cappellini GC, Terzoli E. 
Service of Complementary Medical Oncology, Regina Elena Cancer Institute, Rome, Italy. 
&&url PMID: 10840931 


3. Crit Rev Oncol Hematol 2000 Feb;33(2):137-42 
<b>Steroidal aromatase inhibitors in elderly patients.</b> 
Bajetta E, Zilembo N, Bichisao E, Pozzi P, Toffolatti L . 
Division of Medical Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy. 
&&url PMID: 10737375 


4. Endocr Relat Cancer 1999 Mar;6(1):75-92 
<b>Use of aromatase inhibitors in breast carcinoma.</b> 
Santen RJ, Harvey HA. 
Department of Medicine, University of Virginia Health Sciences Center, Charlottesville 22908, USA. 

"Aromatase, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to estrogens, is the major mechanism of estrogen synthesis in the post-menopausal woman. .... Inhibition of aromatase, the terminal step in estrogen biosynthesis, provides a way of treating hormone-dependent breast cancer in older patients. ... Currently available aromatase inhibitors are safe and effective in the management of hormone-dependent breast cancer in post-menopausal women failing antiestrogen therapy and should now be used before progestational agents." 
&&url PMID: 10732791 


5. Ann Oncol 1999 Apr;10(4):377-84 
<b>The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer.</b> 
Hamilton A, Piccart M. Institut Jules Bordet, Brussels, Belgium. 

" In 1999, tamoxifen remains the first choice in the hormonal therapy of breast cancer. Following tamoxifen failure, the optimal second-line hormonal therapy remains undefined, but aminoglutethimide and megestrol acetate are no longer optimal therapy in this setting. " 
&&url PMID: 10370778 


6. Ann Oncol 1998 Jun;9(6):639-45 
<b>Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer.</b> 
Letrozole International Trial Group (AR/BC3). Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M. N. N. Petrov Research Institute of Oncology, St. Petersburg, Russia. 
&&url PMID: 9681078 


7. Oncology (Huntingt) 1998 Mar;12(3 Suppl 5):32-5 
<b>Emerging role of aromatase inhibitors in the treatment of breast cancer.</b> 
Harvey HA. Section of Hematology-Oncology, Hershey Medical Center, Penn State Geissinger Health Systems, Hershey, Pennsylvania, USA.  
&&url PMID: 9556789 